Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Number of holders
-
25
-
Total principal
-
66.8M
-
Principal change
-
+5.25M
-
Total reported value, excl. options
-
$66.4M
-
Value change
-
+$5.27M
-
Number of buys
-
6
-
Number of sells
-
-4
-
Price
-
$0.99
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q1 2023
25 filings reported holding 53220KAF5 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q1 2023.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $66.8M of principal
.
Largest 10 bondholders include OAKTREE CAPITAL MANAGEMENT LP ($10.7M of principal), Cohanzick Management, LLC ($9.86M of principal), RiverPark Advisors, LLC ($9.86M of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($7.5M of principal), PALISADE CAPITAL MANAGEMENT, LP ($6.27M of principal), Voya Investment Management LLC ($5M of principal), WESTWOOD HOLDINGS GROUP INC ($4M of principal), Radcliffe Capital Management, L.P. ($3.12M of principal), SCHRODER INVESTMENT MANAGEMENT GROUP ($3M of principal), and Russell Investments Group, Ltd. ($2.54M of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.